RT Journal Article
SR Electronic
A1 Alexander, Lori
T1 Phase 2 Trial Provides Safety and Outcomes Data on Novel Anticoagulant Agent
JF MD Conference Express
YR 2009
FD SAGE Publications
VO 8
IS 8
SP 14
OP 15
DO 10.1177/155989770900800806
UL http://mdc.sagepub.com/content/8/8/14.2.abstract
AB Despite the advent of dual antiplatelet therapy with aspirin and clopidogrel, rates of in-hospital and 1-year mortality and reinfarction after acute coronary syndrome (ACS) are approximately 10%. The results of the ATLAS ACS-TIMI 46 [NCT00402597] trial represent an important step toward meeting a need for more effective antithrombotic therapy after ACS.